Alamar Biosciences Announces Launch of NULISAqpcr AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a…
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology
Schlieren, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Round co-led by Ventura…
Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS
Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in…
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic…
